Holen Sie sich die Stockscreener-App
187.21
0.08%
0.15
Handel nachbörslich:
187.21
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$187.06
Offen:
$186.28
24-Stunden-Volumen:
626.56K
Relative Volume:
0.51
Marktkapitalisierung:
$27.64B
Einnahmen:
$9.60B
Nettoeinkommen (Verlust:
$1.37B
KGV:
20.09
EPS:
9.3182
Netto-Cashflow:
$2.32B
1W Leistung:
+3.62%
1M Leistung:
+5.57%
6M Leistung:
+25.37%
1J Leistung:
+51.55%
1-Tages-Spanne:
$185.44
$187.51
1-Wochen-Bereich:
$180.18
$195.98
52-Wochen-Spanne:
$115.25
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
187.21 | 27.62B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
967.93 | 862.01B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.20 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
208.16 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
183.46 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.11 | 277.02B | 65.59B | 8.93B | 12.36B | 3.5532 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Hochstufung | UBS | Neutral → Buy |
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Apellis (APLS) revises executive separation plan tied to Biogen merger - Stock Titan
How Investors Are Reacting To Biogen (BIIB) Earnings Beat, Lower Guidance, And Felzartamab China Deal - simplywall.st
Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Artemis Investment Management LLP Buys Shares of 226,845 Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Freedom Broker upgrades Biogen stock rating on Apellis acquisition By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Citigroup Adjusts Biogen Price Target to $200 From $190 - marketscreener.com
Assessing Biogen (BIIB) Valuation After Strong 1 Year Gains And Mixed Longer Term Returns - simplywall.st
H.C. Wainwright reiterates Biogen stock rating on tau therapy trial - Investing.com
Biogen Inc. (NASDAQ:BIIB) Short Interest Up 15.4% in April - MarketBeat
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Goldman Sachs Adjusts Biogen Price Target to $250 From $238 - marketscreener.com
Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings - Benzinga
Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH) - The Globe and Mail
Biogen Inc. (NASDAQ:BIIB) Q1 2026 Earnings Call Transcript - Insider Monkey
Guggenheim raises Biogen stock price target to $260 on strong Q1 results - Investing.com
Biogen Inc. Stock (US09062X1037): Analyst Rating Changes and Q1 2026 Earnings Preview - AD HOC NEWS
Biogen Inc (BIIB) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
Biogen (BIIB) One Off US$1.1b Loss Tests Bullish Earnings Growth Narrative - simplywall.st
Is Biogen (BIIB) 2.7% Undervalued After Q1 2026? Non-GAAP EPS $3 - GuruFocus
A Look at Biogen Inc (BIIB) After 6.0% Gain -- GF Value $199.82 vs Price $194.38 - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Vanguard Capital Management (NASDAQ: BIIB) reports 10.99M Biogen shares ownership - Stock Titan
Biogen beats estimates as Alzheimer’s drug gains momentum - The Boston Globe
Biogen Inc. (BIIB.US) 1Q Earnings and Revenue Beat Forecasts - AASTOCKS.com
BofA raises Biogen stock price target on solid quarterly results - Investing.com
BofA raises Biogen stock price target on solid quarterly results By Investing.com - Investing.com Canada
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Biogen Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Biogen Q1 2026 slides: EPS beats forecast, Apellis deal to boost growth - Investing.com
Biogen Q1 Earnings Call Highlights - Yahoo Finance
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs - Yahoo Finance
Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge - TechStock²
Earnings call transcript: Biogen Q1 2026 beats expectations with strong EPS and revenue growth - Investing.com
Biogen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Vanguard Group Inc. Has $3.07 Billion Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Reports Strong Q1 Earnings, Raises 2026 EPS Guidan - GuruFocus
Biogen Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BIIB) 2026-04-29 - Seeking Alpha
Biogen (BIIB) Projects Revenue Decline and Adjusts EPS Forecast for 2026 - GuruFocus
Biogen cuts annual profit forecast on acquisition-related charges - marketscreener.com
Biogen trims full-year earnings outlook on BD impact - MSN
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Biogen Q1 Non-GAAP Earnings, Revenue Rise; Cuts 2026 Earnings Outlook - marketscreener.com
Biogen (NASDAQ: BIIB) boosts profit and cash flow, plans $5.6B Apellis buy - Stock Titan
Biogen posts Q1 beat, trims earnings outlook (BIIB:NASDAQ) - Seeking Alpha
Biogen (NASDAQ:BIIB) Surprises With Q1 CY2026 Sales - Yahoo Finance
Apellis deal and Q1 2026 results reshape Biogen (NASDAQ: BIIB) outlook - Stock Titan
Biogen : BIIB Q1 26 Earnings Presentation Final - marketscreener.com
Biogen : Q1 2026 Earnings Press Release Final - marketscreener.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):